Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK2 | P24941 | 10/20 | 0.79 |
| ▸ | PKM | P14618 | 3/20 | 0.67 |
| ▸ | MEN1 | O00255 | 3/20 | 0.67 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.67 |
| ▸ | MAPT | P10636 | 3/20 | 0.67 |
| ▸ | LMNA | P02545 | 2/20 | 0.67 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.67 |
| ▸ | HTT | P42858 | 1/20 | 0.67 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.67 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.67 |
| ▸ | NPC1 | O15118 | 1/20 | 0.60 |
| ▸ | RAB9A | P51151 | 1/20 | 0.60 |
| ▸ | PKLR | P30613 | 1/20 | 0.52 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.51 |
| ▸ | POLB | P06746 | 1/20 | 0.51 |
| ▸ | GAA | P10253 | 1/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | MC5R | P33032 | 1/20 | 0.49 |
| ▸ | MC3R | P41968 | 1/20 | 0.49 |
| ▸ | MC1R | Q01726 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26979046 | 0.89 | CDK2 (1.00) | CDK2PKMMEN1KMT2AMAPT | |
| SCHEMBL4652603 | 0.86 | CDK2 (0.61) | CDK2PKMMEN1KMT2AMAPT | |
| SCHEMBL2243271 | 0.84 | MAPT (0.71) | CDK2PKMMEN1KMT2AMAPT | |
| SCHEMBL4652444 | 0.84 | CDK2 (0.74) | CDK2PKMMEN1KMT2AMAPT | |
| SCHEMBL2243473 | 0.83 | MEN1 (0.72) | CDK2PKMMEN1KMT2AMAPT | |
| SCHEMBL8222876 | 0.83 | PKM (0.72) | CDK2PKMMEN1KMT2AMAPT | |
| SCHEMBL6408868 | 0.83 | HTR2A (0.61) | CDK2MEN1KMT2AMAPTNPSR1 | |
| SCHEMBL2243629 | 0.81 | CDK2 (0.71) | CDK2PKMMEN1KMT2AMAPT | |
| SCHEMBL18531470 | 0.80 | MAPT (0.64) | CDK2PKMMEN1KMT2AMAPT | |
| SCHEMBL18531434 | 0.78 | CDK2 (0.68) | CDK2PKMMEN1KMT2AMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-100518735-C | Derivatives of tryptamine and analogous compounds, and pharmaceutical formulations containing them | NEURIM PHARMA 1991 (IL) | 2009-07-29 | — | — | CN | claimed |
| CN-1582147-A | Tryptamine derivatives and analogues and pharmaceutical compositions containing them | NEURIM PHARMA 1991 (IL) | 2005-02-16 | — | — | CN | claimed |
| EP-1331935-A4 | DERIVATIVES OF TRYPTAMINE AND ANALOGOUS COMPOUNDS, AND PHARMACEUTICAL FORMULATIONS CONTAINING THEM | NEURIM PHARMA 1991 (IL) | 2004-12-01 | — | — | EP | claimed |
| US-6780884-B2 | NOVEL COMPOUNDS RELATED TO MELATONIN, BUT WITH PHARMACOLOGICAL OR PHARMACOKINETIC PROFILES DIFFERENT FROM MELATONIN | NEURIM PHARMACEUTICALS (1991) LTD. (IL) | 2004-08-24 | — | — | US | claimed |
| US-20040029950-A1 | Derivating of tryptamine and analogous componds and pharmaceutical formulations containing them | NEURIM PHARMACEUTICALS (1991) LTD. (IL) | 2004-02-12 | — | — | US | claimed |
| EP-1331935-A2 | DERIVATIVES OF TRYPTAMINE AND ANALOGOUS COMPOUNDS, AND PHARMACEUTICAL FORMULATIONS CONTAINING THEM | NEURIM PHARMACEUTICALS (1991) LIMITED (IL) | 2003-08-06 | — | — | EP | claimed |
| WO-2002028347-A2 | DERIVATIVES OF TRYPTAMINE AND ANALOGOUS COMPOUNDS, AND PHARMACEUTICAL FORMULATIONS CONTAINING THEM | NEURIM PHARMACEUTICALS (1991) LTD. (IL) | 2002-04-11 | — | — | WO | claimed |
| CN-100518735-C | Derivatives of tryptamine and analogous compounds, and pharmaceutical formulations containing them | NEURIM PHARMA 1991 (IL) | 2009-07-29 | — | — | CN | disclosed |
| EP-1331935-B1 | DERIVATIVES OF TRYPTAMINE AND ANALOGOUS COMPOUNDS, AND PHARMACEUTICAL FORMULATIONS CONTAINING THEM | NEURIM PHARMA 1991 (IL) | 2008-10-01 | — | — | EP | disclosed |
| CN-1582147-A | Tryptamine derivatives and analogues and pharmaceutical compositions containing them | NEURIM PHARMA 1991 (IL) | 2005-02-16 | — | — | CN | disclosed |
| US-20050020664-A1 | Derivatives of tryptamine and analogous compounds, and pharmaceutical formulations containing them | NEURIM PHARMACEUTICALS (1991) LTD. (IL) | 2005-01-27 | — | — | US | disclosed |
| EP-1331935-A4 | DERIVATIVES OF TRYPTAMINE AND ANALOGOUS COMPOUNDS, AND PHARMACEUTICAL FORMULATIONS CONTAINING THEM | NEURIM PHARMA 1991 (IL) | 2004-12-01 | — | — | EP | disclosed |
| US-6780884-B2 | NOVEL COMPOUNDS RELATED TO MELATONIN, BUT WITH PHARMACOLOGICAL OR PHARMACOKINETIC PROFILES DIFFERENT FROM MELATONIN | NEURIM PHARMACEUTICALS (1991) LTD. (IL) | 2004-08-24 | — | — | US | disclosed |
| US-20040029950-A1 | Derivating of tryptamine and analogous componds and pharmaceutical formulations containing them | NEURIM PHARMACEUTICALS (1991) LTD. (IL) | 2004-02-12 | — | — | US | disclosed |
| EP-1331935-A2 | DERIVATIVES OF TRYPTAMINE AND ANALOGOUS COMPOUNDS, AND PHARMACEUTICAL FORMULATIONS CONTAINING THEM | NEURIM PHARMACEUTICALS (1991) LIMITED (IL) | 2003-08-06 | — | — | EP | disclosed |
| WO-2002028347-A2 | DERIVATIVES OF TRYPTAMINE AND ANALOGOUS COMPOUNDS, AND PHARMACEUTICAL FORMULATIONS CONTAINING THEM | NEURIM PHARMACEUTICALS (1991) LTD. (IL) | 2002-04-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050020664-A1 | Derivatives of tryptamine and analogous compounds, and pharmaceutical formulations containing them | TPH1, TPH2, TPSB2 | CDK2 335/4885PKM 785/4885MEN1 50/4885 |
| US-20040029950-A1 | Derivating of tryptamine and analogous componds and pharmaceutical formulations containing them | TPH2, TPH1, TPSD1 | CDK2 66/4885PKM 140/4885MEN1 306/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.